Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned ... small molecule therapeutics targeting fundamental biological ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological ...

(Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics ... registration-enabling DENALI Part 2 study ...

Deutsche Bank initiated coverage of Denali Therapeutics (DNLI) with a Buy rating and $31 price target Maximize Your Portfolio with Data Driven ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Buy ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.33. The stock has a market capitalization of $3.14 billion, a PE ratio of -7.91 and a beta of 1.43.

Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24 ...

SG Americas Securities LLC increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 128.8% in the 4th quarter, according to the company in its most recent ...